Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FER | P16591 | 1/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8127618 | 0.75 | MAPT (0.57) | MAPTALDH1A1KDM4EHPGDCYP1A2 | |
| SCHEMBL31397805 | 0.75 | PDK2 (0.59) | MAPTALDH1A1KDM4EHPGDCYP1A2 | |
| SCHEMBL842406 | 0.75 | PDK2 (0.59) | MAPTALDH1A1KDM4EHPGDCYP1A2 | |
| SCHEMBL14703200 | 0.74 | ALDH1A1 (0.55) | MAPTALDH1A1KDM4EMAOAMAOB | |
| SCHEMBL318947 | 0.74 | PDK2 (0.57) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL29651321 | 0.74 | PDK2 (0.57) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL17941991 | 0.73 | CA1 (0.42) | MAPTALDH1A1KDM4EIDO1 | |
| SCHEMBL31212236 | 0.73 | CA1 (0.42) | MAPTALDH1A1KDM4EIDO1 | |
| SCHEMBL3865758 | 0.69 | MMP2 (0.56) | MAPTALDH1A1KDM4EHPGDCYP1A2 | |
| SCHEMBL15193970 | 0.69 | KDR (0.50) | MAPTALDH1A1KDM4EHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688791-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4469164-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024208934-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024169914-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | MAPT 3834/4885ALDH1A1 462/4885KDM4E 2186/4885 |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | MAPT 3834/4885ALDH1A1 462/4885KDM4E 2186/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | MAPT 3834/4885ALDH1A1 462/4885KDM4E 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.